New drug combo shows promise for ALK-Positive lung cancer patients
NCT ID NCT02393625
First seen Feb 03, 2026 · Last updated May 08, 2026 · Updated 11 times
Summary
This early-stage study tests the safety and effectiveness of combining two drugs, ceritinib and nivolumab, in adults with a specific genetic type of advanced lung cancer called ALK-positive NSCLC. The goal is to find the best dose and see if the combination shrinks tumors. About 57 participants will receive the treatment, and researchers will monitor side effects and how long any benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Massachusetts General Hospital Thoracic Oncolgoy
Boston, Massachusetts, 02115, United States
-
Mayo Clinic - Arizona
Scottsdale, Arizona, 85259, United States
-
Novartis Investigative Site
Heidelberg, Victoria, 3084, Australia
-
Novartis Investigative Site
Leuven, Vlaams Brabant, 3000, Belgium
-
Novartis Investigative Site
Toronto, Ontario, M5G 2M9, Canada
-
Novartis Investigative Site
Hong Kong, 999077, Hong Kong
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Modena, MO, 41124, Italy
-
Novartis Investigative Site
Singapore, 168583, Singapore
-
Novartis Investigative Site
Barcelona, 08035, Spain
Conditions
Explore the condition pages connected to this study.